PCRX (Pacira BioSciences) 10-Year Sharpe Ratio : -0.08 (As of Jul. 10, 2025)

View and export this data going back to 2011. Start your Free Trial

What is Pacira BioSciences 10-Year Sharpe Ratio?

The 10-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past ten years. As of today (2025-07-10), Pacira BioSciences's 10-Year Sharpe Ratio is -0.08.

Competitive Comparison of Pacira BioSciences's 10-Year Sharpe Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's 10-Year Sharpe Ratio, along with its competitors' market caps and 10-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pacira BioSciences's 10-Year Sharpe Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's 10-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Pacira BioSciences's 10-Year Sharpe Ratio falls into.

Save Embed

;

Save Embed

;

Pacira BioSciences 10-Year Sharpe Ratio Calculation

The 10-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last ten years. A stock / portfolio's 10-Year Sharpe Ratio can be calculated by dividing the difference between the ten-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past ten years.

Pacira BioSciences (NAS:PCRX) 10-Year Sharpe Ratio Explanation

The 10-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past ten years. It is calculated as the annualized result of the average ten-year monthly excess returns divided by its standard deviation in the ten-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Pacira BioSciences 10-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of Pacira BioSciences's 10-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Pacira BioSciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pacira BioSciences Inc (NAS:PCRX) » Definitions » 10-Year Sharpe Ratio

Comparable Companies

Traded in Other Exchanges

82P:Germany

Address

5401 West Kennedy Boulevard, Suite 890, Tampa, FL, USA, 33609

Website

https://www.pacira.com

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Executives

Jonathan Slonin	officer: Chief Clinical Officer	C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Daryl Gaugler	officer: Chief Operating Officer	C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Marcelo Bigal	director	C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA FL 33609
Laura Brege	director	C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608
Michael J. Yang	director	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Mark Froimson	director	5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Kristen Marie Williams	officer: CAO and General Counsel	C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Paul J Hastings	director	61 HARTFORD STREET, SAN FRANCISCO CA 94114
Lauren Bullaro Riker	officer: Executive Director, Accounting	C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054
Gary W Pace	director	C/O RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Alethia Young	director	C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Abraham Ceesay	director	C/O SCPHARMACEUTICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01830
Roy Winston	officer: Chief Clinical Officer	C/O PACIRA BIOSCIENCES, INC,, 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA FL 33609
Mark A. Kronenfeld	director	C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 100, PARSIPPANY NJ 07054
Reinhart Charles A. Iii	officer: Chief Financial Officer	C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054